The overall patient response to ICI is heterogeneous with most cancer types showing response rates ranging from 15% to 40%, based on the tumour type,13 while CTLA‐4 therapy delivers an objective response rate of 20% in metastatic melanoma patients.14 The gene discussed is CTLA4; the disease is metastatic melanoma.